Sodium Valproate and Topiramate Monitoring Report to September 2026

NISRA Northern Ireland Statistics and Research Agency
Gníomhaireacht Thuaisceart Éireann um Staitistiocí agus Taighde

HSC Business Services Organisation
Family Practitioner Services




In April-September 2026:

- **719 females** and **2,265 males** aged 0-54 were prescribed and dispensed **Sodium Valproate**
- This was a decrease of **53%** for females and **31%** for males since April 2019

- **815 females** and **406 males** aged 0-54 were prescribed and dispensed **Topiramate**
- Female patients have decreased by **32%** and males by **9%** since April 2023







Eleven females and **thirty-two** males under the age of 55 **started** on Sodium Valproate between **July and September 2026**

The number of patients **starting Topiramate** in this period was **thirty-two females** and **thirty-two males** aged 0-54

The **rate of verifiable female patients** under 55 prescribed Sodium Valproate per 1,000 population in Northern Ireland was **1.03**, and **3.06 for males** in April-September 2026



The equivalent rate for patients prescribed **Topiramate** was **1.17** per 1,000 females and **0.55** per 1,000 males aged 0-54



Proportion of female patients aged 13-44, as a % of all Sodium Valproate (left) or Topiramate (right) patients in each **HSC Trust** Apr-Sep 2026

